OTSUKA PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients With Alcohol Dependence
Active, not recruiting
- Conditions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 533
- Registration Number
- NCT04107051
- Locations
- π―π΅
Otsuka Pharmaceutical Co., Ltd., Osaka, Japan
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04049825
- Locations
- π―π΅
Yamagata University Hospital, Yamagata, Japan
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03962101
- Locations
- π―π΅
Gifu Prefectural General Medical Center, Gifu, Japan
Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT03961529
- Locations
- π―π΅
Shirao clinic of pediatrics and pediatric allergy, Hiroshima, Japan
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 251
- Registration Number
- NCT03911401
- Locations
- π―π΅
Kato Dermatology Clinic, Sapporo, Japan
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT03908970
- Locations
- π―π΅
Kitago Hifuka Clinic, Sapporo, Japan
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03906695
- Locations
- π―π΅
NTT Medical Center Tokyo, Tokyo, Japan
Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03902574
- Locations
- π―π΅
SOUSEIKAI Hakata clinic, Fukuoka, Japan
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT03772041
- Locations
- π―π΅
Saiseikai Kumamoto Hospital, Kumamoto, Japan
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT03737474
- Locations
- π―π΅
Nanko-kokorono clinic, Shirakawa, Japan
Β© Copyright 2024. All Rights Reserved by MedPath